CATHERINE LASPERCHES: Open Payments
NPI 1205857224 · NEW ORLEANS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$806 in 7 payments from 7 companies in 2025. Trend: 2023 $623 · 2024 $636 · 2025 $806
Food & beverage: $806
| Company | Payments | Amount |
|---|---|---|
| Dexcom, Inc. | 1 | $163 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $140 |
| Janssen Biotech, Inc. | 1 | $137 |
| Madrigal Pharmaceuticals | 1 | $123 |
| Teva Pharmaceuticals USA, Inc. | 1 | $117 |
| GENZYME CORPORATION | 1 | $110 |
| ABBVIE INC. | 1 | $15 |
Products named: DEXCOM G7 GSS (161), Kerendia, REZDIFFRA, UZEDY, DUPIXENT, UBRELVY.
Industry payments across LA — which companies pay providers there.
